FDA approves Tagrisso for 1st-line use in NSCLC
19 April 2018 07:00 BST US FDA APPROVES TAGRISSO AS 1ST-LINE TREATMENT FOR EGFR-MUTATEDNON-SMALL CELL LUNG CANCER 1st-line use of Tagrisso offers potential new standard of care Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR)